Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

FLUOXETINE HCL

All products: not a benefit

Other products in the same Health Canada class (N06A, N06AB) — coverage varies; not interchangeable

  • Citalopram (Celexa): general benefit, Not a benefit
  • Escitalopram (Cipralex MELTZ): general benefit, Not a benefit
  • Fluvoxamine (Luvox): general benefit
  • Paroxetine (Paxil): general benefit, Not a benefit
  • Sertraline (Zoloft): general benefit
  • Amitriptyline (Elavil): general benefit

17 more in the class list below

PMS-Fluoxetine · DIN 02177579 · 10mg · capsule

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-19
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Fluoxetine · DIN 02177579 Manufacturer: Pharmascience Inc.; listing date 2008-02-12 Health Canada: Marketed since 2001-12-22 · brand PMS-FLUOXETINE · ATC N06AB03 FLUOXETINE · form Capsule · route Oral · ingredients FLUOXETINE (FLUOXETINE HYDROCHLORIDE) 10 MG · company Daiichi sankyo pharma canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19074 · Verify on the e-Formulary ↗ (DIN 02177579)

Source record
DIN 02177579: PMS-Fluoxetine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604122; group id 461; item number 1154; lccId None; manufacturer id PMS Source form: Cap; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.1773; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02177579 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19074
Interchangeable products
AG-Fluoxetine · DIN 02485052 · not recorded Ach-Fluoxetine · DIN 02393441 · not recorded Apo-Fluoxetine · DIN 02216353 · not recorded Auro-Fluoxetine · DIN 02385627 · not recorded Bio-Fluoxetine · DIN 02448424 · not recorded Co Fluoxetine · DIN 02242177 · not recorded Fluoxetine · DIN 02286068 · not recorded Fluoxetine · DIN 02374447 · not recorded Jamp-Fluoxetine · DIN 02401894 · not recorded M-Fluoxetine · DIN 02529432 · not recorded Mar-Fluoxetine · DIN 02392909 · not recorded Mint-Fluoxetine · DIN 02380560 · not recorded NRA-Fluoxetine · DIN 02503875 · not recorded Prozac · DIN 02018985 · not recorded Sandoz Fluoxetine · DIN 02479486 · not recorded Teva-Fluoxetine · DIN 02216582 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (28:16:04 Antidepressants) and how they are covered

Matched class: 28:16:04 Antidepressants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMITRIPTYLINE, CLOMIPRAMINE HCL, FLUVOXAMINE MALEATE, NORTRIPTYLINE, PHENELZINE SULFATE, SERTRALINE HCL, TRANYLCYPROMINE SULFATE, VENLAFAXINE HCL, VORTIOXETINE HYDROBROMIDE Some products covered without a code (check the product listing): CITALOPRAM HYDROBROMIDE, DESIPRAMINE, DOXEPIN HCL, DULOXETINE, ESCITALOPRAM, IMIPRAMINE, MIRTAZAPINE, MOCLOBEMIDE, PAROXETINE HCL, TRAZODONE HYDROCHLORIDE, TRIMIPRAMINE 28:16:04 Antidepressants

CITALOPRAM HYDROBROMIDE

· 51 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (42) · strengths: 10mg, 20mg, 40mg · Tab

ESCITALOPRAM

· 40 products · Listed, not a benefit (2), General benefit (38) · strengths: 10mg, 20mg · Orally Disintegrating Tab, Orally Disintegrating Tablet, Tab

FLUVOXAMINE MALEATE

· 6 products · General benefit · strengths: 50mg, 100mg · Tab

PAROXETINE HCL

· 47 products · Off-Formulary Interchangeable, not an ODB benefit (16), General benefit (31) · strengths: 10mg, 20mg, 30mg · Tab

SERTRALINE HCL

· 49 products · General benefit · strengths: 25mg, 50mg, 100mg · Cap

AMITRIPTYLINE

· 12 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

CLOMIPRAMINE HCL

· 5 products · General benefit · strengths: 25mg, 50mg, 10mg · Tab

DESIPRAMINE

· 7 products · Listed, not a benefit (4), General benefit (3) · strengths: 25mg, 50mg, 75mg · Tab

DOXEPIN HCL

· 20 products · General benefit (12), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Cap

DULOXETINE

· 38 products · Listed, not a benefit (2), General benefit (36) · strengths: 30mg, 60mg · DR Cap

IMIPRAMINE

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 10mg, 25mg, 50mg · Tab

MIRTAZAPINE

· 25 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 15mg, 30mg, 45mg · Orally Disintegrating Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:04 and 12 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: major depressive disorder, obsessive-compulsive disorder
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: BREXPIPRAZOLE, FLUVOXAMINE MALEATE, SERTRALINE HCL, VORTIOXETINE HYDROBROMIDE BREXPIPRAZOLE · General benefit • use as an adjunct to antidepressants for the treatment of major depressive disorder (MDD) in adult patients with an inadequate response to prior antidepressant treatments during the current episode (see 14.1 Clinical Trials by Indication, Adjunctive Treatment in Major Depressive Disorder (MDD). PM: https://pdf.hres.ca/dpd_pm/00074327.PDF; date February 16, 2017; DIN 02461749; fetched 2026-09-10 Product monograph DESVENLAFAXINE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS PRISTIQ (desvenlafaxine succinate) is indicated for: • symptomatic relief of major depressive disorder in adults. PM: https://pdf.hres.ca/dpd_pm/00074568.PDF; date FEB 04, 2009; DIN 02321092; fetched 2026-09-10 Product monograph DULOXETINE · Listed, not a benefit (2), General benefit (36) 1 Indications pms-DULOXETINE (Duloxetine Delayed-Release Capsules) is indicated in adults for: • Major Depressive Disorder pms-DULOXETINE is indicated for the symptomatic relief of major depressive disorder (MDD). PM: https://pdf.hres.ca/dpd_pm/00084896.PDF; date 2026-05-29; DIN 02429446; fetched 2026-09-10 Product monograph FLUVOXAMINE MALEATE · General benefit  Obsessive-Compulsive Disorder: PM: https://pdf.hres.ca/dpd_pm/00062197.PDF; date JAN 9, 1991; DIN 01919342; fetched 2026-09-10 Product monograph SERTRALINE HCL · General benefit Therefore, the health professional who elects to use ZOLOFT for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient.  Obsessive-Compulsive Disorder ZOLOFT is indicated for the symptomatic relief of obsessive-compulsive disorder (OCD). PM: https://pdf.hres.ca/dpd_pm/00072140.PDF; date AUG 22, 2023; DIN 01962779; fetched 2026-09-10 Product monograph VILAZODONE HYDROCHLORIDE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS VIIBRYD (vilazodone hydrochloride tablets) is indicated for the symptomatic relief of Major Depressive Disorder (MDD). PM: https://pdf.hres.ca/dpd_pm/00073801.PDF; date JUL 15, 2015; DIN 02443724; fetched 2026-09-10 Product monograph VORTIOXETINE HYDROBROMIDE · General benefit 1 Indications TRINTELLIX (vortioxetine hydrobromide) is indicated for: • the treatment of major depressive disorder (MDD) in adults. PM: https://pdf.hres.ca/dpd_pm/00085298.PDF; date 2026-07-10; DIN 02432919; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS pms-FLUOXETINE (fluoxetine) is indicated in adults for: • Depression: pms-FLUOXETINE is indicated for the symptomatic relief of Major Depressive Disorder (MDD). • Bulimia Nervosa: Fluoxetine has been shown to significantly decrease binge-eating and purging activity when compared with placebo treatment. • Obsessive-Compulsive Disorder (OCD): pms-FLUOXETINE is indicated for the symptomatic treatment of obsessive-compulsive disorder (OCD). The obsessions or compulsions must be experienced as intrusive, markedly distressing, time consuming, or interfering significantly with the person’s social or occupational functioning. The efficacy of fluoxetine in hospitalized patients has not been adequately studied. Long-term use of fluoxetine: The effectiveness of fluoxetine in long-term use in bulimia nervosa (i.e., for more than 16 weeks) and in obsessive-compulsive disorder (i.e., for more than 13 weeks) has not been systematically evaluated in controlled trials. Therefore, the health professional who elects to use pms-FLUOXETINE in these indications for extended periods … https://pdf.hres.ca/dpd_pm/00076968.PDF PM date: AUG 30, 2024 Source product: PMS-FLUOXETINE; DIN 02177579; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For PMS-Fluoxetine: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026